Hikma Stands Firm On Supply As It Scoffs At Latest Amarin Lawsuit

Motion To Dismiss Filed; Advair Expectations Disclosed

 
• By Dean Rudge

Hikma addressed supply concerns and the latest legal worries for its generic Vascepa product, as well as the recent launch of its long-awaited Advair generic, as management faced the virtual J.P. Morgan Healthcare Conference.

Fish oil with capsules
Hikma has so far taken a Vascepa market share of around 10%-12% following market entry in November. • Source: Shutterstock

More from Generics

More from Products